Felpreva (tigolaner/emodepside/praziquantel)
Broad-spectrum parasitic treatment for cats
ApprovedCommercial (Launched 2023)
Key Facts
Indication
Broad-spectrum parasitic treatment for cats
Phase
Approved
Status
Commercial (Launched 2023)
Company
About Vetoquinol
Vetoquinol is an independent, family-founded animal health company with a mission to improve animal health and well-being through innovative pharmaceutical solutions. The company has built a strong international presence, generating over €500 million in annual revenue through a direct commercial footprint in key markets and a network of distributors. Its strategy focuses on therapeutic innovation, geographic expansion, and strategic acquisitions to strengthen its position in the high-growth animal health market, which is driven by trends in pet humanization, food safety, and livestock productivity.
View full company profile